Vernal Keratoconjunctivitis Market
In 2017, the total prevalent population of Vernal Keratoconjunctivitis in the major markets (which includes the USA, Germany, France, the UK, Italy, Spain, Japan, China, Egypt, Saudi Arabia, and Russia) was found to be 4,752,356 and is expected to increase during the forecast period 2017-2030. The market size of Vernal Keratoconjunctivitis in the major markets (i.e. 7MM, China, Egypt, Saudi Arabia, and Russia) was USD 307.89 Million in 2017. The key factors such as rise in prevalence, disease awareness & diagnosis, and research & development are expected to drive the VKC market forward in the coming years. The key players in the Vernal Keratoconjunctivitis market include Allakos Inc., iCo Therapeutics, Akari Therapeutics, Santen, Novartis, Alcon, Senju Pharmaceutical, and many others. For more detailed information on Vernal Keratoconjunctivitis market, visit: https://www.delveinsight.com/report-store/vernal-keratoconjunctivitis-market
31 views • 1 slides
